CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney

Nastase, Madalina Viviana, Zeng-Brouwers, Jinyang, Beckmann, Janet, Tredup, Claudia, Christen, Urs, Radeke, Heinfried H., Wygrecka, Malgorzata, Schaefer, Liliana·2018·Matrix Biology
DOI 10.1016/j.matbio.2017.12.002
Open this paper in CoChat — free account

Abstract

Th1 and Th17 cells, T helper (Th) subtypes, are key inducers of renal fibrosis. The molecular mechanisms of their recruitment into the kidney, however, are not well understood. Here, we show that biglycan, a proteoglycan of the extracellular matrix, acting in its soluble form as a danger signal, stimulates autonomously the production of Th1 and Th17 chemoattractants CXCL10 and CCL20 in macrophages. In the presence of IFNγ, biglycan synergistically stimulates CXCL9. In macrophages deficient for TLR2, TLR4, and their adaptor molecules MyD88 or TRIF, we identified highly selective mechanisms of biglycan-dependent Th1/17 chemoattraction. Thus, the expression of CXCL9 and CXCL10, common chemoattractants for CXCR3-positive Th1 and Th17 cells, is triggered in a biglycan-TLR4/TRIF-dependent manner. By contrast, biglycan induces CCL20 chemokine production, responsible for CCR6-positive Th17 cell recruitment, in a TLR2/4/MyD88-dependent manner. Importantly, at the onset of diabetes mellitus and lupus nephritis we provide evidence for biglycan-dependent recruitment of Th1 and Th17 cells, IFNγ and IL-17 production, and development of albuminuria in mice lacking or overexpressing soluble biglycan. Furthermore, by genetic ablation of Cxcl10 we showed in vivo involvement of this chemokine in biglycan-dependent recruitment of Th1 and Th17 cells into the kidney. Finally, a positive correlation of biglycan and CXCL10/CXCL9 levels was detected in plasma from patients with diabetic nephropathy a…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.matbio.2017.12.002

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 78

  1. Hill, 2016, Global prevalence of chronic kidney disease - a systematic review and meta-analysis, PLoS One, 11, 10.1371/journal.pone.0158765 · DOI
  2. Anand, 2017, Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries, BMJ Glob. Health, 2, 10.1136/bmjgh-2017-000453 · DOI
  3. Stanifer, 2016, Chronic kidney disease in low- and middle-income countries, Nephrol. Dial. Transplant., 31, 868, 10.1093/ndt/gfv466 · DOI
  4. Kiuchi, 2016, Chronic kidney disease and risk factors responsible for sudden cardiac death: a whiff of hope?, Kidney Res. Clin. Pract., 35, 3, 10.1016/j.krcp.2015.11.003 · DOI
  5. Klinkhammer, 2017, Treatment of renal fibrosis-turning challenges into opportunities, Adv. Chronic Kidney Dis., 24, 117, 10.1053/j.ackd.2016.11.002 · DOI
  6. Dolman, 2010, Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells, Adv. Drug Deliv. Rev., 62, 1344, 10.1016/j.addr.2010.07.011 · DOI
  7. Breyer, 2016, The next generation of therapeutics for chronic kidney disease, Nat. Rev. Drug Discov., 15, 568, 10.1038/nrd.2016.67 · DOI
  8. MacKinnon, 2006, Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data, Am. J. Kidney Dis., 48, 8, 10.1053/j.ajkd.2006.04.077 · DOI
  9. Zhang, 2017, Effects of RAAS inhibitors in patients with kidney disease, Curr. Hypertens. Rep., 19, 72, 10.1007/s11906-017-0771-9 · DOI
  10. Zheng, 2016, Immune cells and inflammation in diabetic nephropathy, J. Diab. Res., 2016, 1841690
  11. Donate-Correa, 2015, Inflammatory cytokines in diabetic nephropathy, J. Diab. Res., 2015, 948417
  12. Segerer, 2008, B cells and tertiary lymphoid organs in renal inflammation, Kidney Int., 73, 533, 10.1038/sj.ki.5002734 · DOI
  13. Kulkarni, 2008, Chemokines in lupus nephritis, Front. Biosci., 13, 3312, 10.2741/2927 · DOI
  14. Bradshaw, 2009, Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells, J. Immunol., 183, 4432, 10.4049/jimmunol.0900576 · DOI
  15. Kim, 2015, Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression, Transl. Res., 166, 375, 10.1016/j.trsl.2015.04.013 · DOI
  16. Moon, 2012, Aberrant recruitment and activation of T cells in diabetic nephropathy, Am. J. Nephrol., 35, 164, 10.1159/000334928 · DOI
  17. Bagavant, 2009, Pathogenesis of kidney disease in systemic lupus erythematosus, Curr. Opin. Rheumatol., 21, 489, 10.1097/BOR.0b013e32832efff1 · DOI
  18. Steinmetz, 2009, CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis, J. Immunol., 183, 4693, 10.4049/jimmunol.0802626 · DOI
  19. Imani, 1993, Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling, J. Exp. Med., 178, 2165, 10.1084/jem.178.6.2165 · DOI
  20. Krebs, 2016, CD4+ T cell fate in glomerulonephritis: a tale of Th1, Th17, and novel Treg subtypes, Mediat. Inflamm., 2016, 5393894, 10.1155/2016/5393894 · DOI
  21. Krebs, 2017, T helper type 17 cells in immune-mediated glomerular disease, Nat. Rev. Nephrol., 13, 647, 10.1038/nrneph.2017.112 · DOI
  22. Kurts, 2013, The immune system and kidney disease: basic concepts and clinical implications, Nat. Rev. Immunol., 13, 738, 10.1038/nri3523 · DOI
  23. Bromley, 2008, Orchestrating the orchestrators: chemokines in control of T cell traffic, Nat. Immunol., 9, 970, 10.1038/ni.f.213 · DOI
  24. Groom, 2011, CXCR3 in T cell function, Exp. Cell Res., 317, 620, 10.1016/j.yexcr.2010.12.017 · DOI
  25. Krebs, 2016, Autoimmune renal disease is exacerbated by S1P-Receptor-1-dependent intestinal Th17 cell migration to the kidney, Immunity, 45, 1078, 10.1016/j.immuni.2016.10.020 · DOI
  26. Segerer, 2004, CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis, Am. J. Pathol., 164, 635, 10.1016/S0002-9440(10)63152-5 · DOI
  27. Karin, 2016, Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets, J. Leukoc. Biol., 99, 857, 10.1189/jlb.2MR0915-441R · DOI
  28. Afzali, 2007, The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease, Clin. Exp. Immunol., 148, 32, 10.1111/j.1365-2249.2007.03356.x · DOI · Paper page
  29. Stockinger, 2017, The dichotomous nature of T helper 17 cells, Nat. Rev. Immunol., 17, 535, 10.1038/nri.2017.50 · DOI
  30. Genovese, 2014, The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?, Fibrogenesis Tissue Repair, 7, 4, 10.1186/1755-1536-7-4 · DOI
  31. Kolset, 2012, Diabetic nephropathy and extracellular matrix, J. Histochem. Cytochem., 60, 976, 10.1369/0022155412465073 · DOI
  32. Moreth, 2014, Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury, Matrix Biol., 35, 143, 10.1016/j.matbio.2014.01.010 · DOI
  33. Iozzo, 2015, Proteoglycan form and function: a comprehensive nomenclature of proteoglycans, Matrix Biol., 42, 11, 10.1016/j.matbio.2015.02.003 · DOI
  34. Schaefer, 2001, Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin, FASEB J., 15, 559, 10.1096/fj.00-0493fje · DOI
  35. Thompson, 2011, Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy, Am. J. Pathol., 179, 1179, 10.1016/j.ajpath.2011.05.016 · DOI
  36. Hsieh, 2014, Soluble biglycan as a biomarker of inflammatory renal diseases, Int. J. Biochem. Cell Biol., 54, 223, 10.1016/j.biocel.2014.07.020 · DOI
  37. Babelova, 2009, Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors, J. Biol. Chem., 284, 24035, 10.1074/jbc.M109.014266 · DOI
  38. Zeng-Brouwers, 2014, De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways, Matrix Biol., 35, 132, 10.1016/j.matbio.2013.12.003 · DOI
  39. Hsieh, 2017, Biglycan- and sphingosine Kinase-1 signaling crosstalk regulates the synthesis of macrophage chemoattractants, Int. J. Mol. Sci., 18, 10.3390/ijms18030595 · DOI
  40. Hsieh, 2016, Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1beta synthesis, Matrix Biol., 49, 61, 10.1016/j.matbio.2015.12.005 · DOI
  41. Nastase, 2017, Signaling at the crossroads: matrix-derived proteoglycan and reactive oxygen species signaling, Antioxid. Redox Signal., 27, 855, 10.1089/ars.2017.7165 · DOI
  42. Eleazu, 2013, Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans, J. Diabetes Metab. Disord., 12, 60, 10.1186/2251-6581-12-60 · DOI
  43. Sakata, 2012, Animal models of diabetes mellitus for islet transplantation, Exp. Diabetes Res., 2012, 256707, 10.1155/2012/256707 · DOI
  44. Sierro, 2007, Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7, Proc. Natl. Acad. Sci. U. S. A., 104, 14759, 10.1073/pnas.0702229104 · DOI
  45. Turner, 2010, CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis, J. Am. Soc. Nephrol., 21, 974, 10.1681/ASN.2009070741 · DOI
  46. Summers, 2009, Th1 and Th17 cells induce proliferative glomerulonephritis, J. Am. Soc. Nephrol., 20, 2518, 10.1681/ASN.2009030337 · DOI
  47. Coppieters, 2013, Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model, Diabetes, 62, 2492, 10.2337/db12-1370 · DOI
  48. Liu, 2006, Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3−/− mice with experimental autoimmune encephalomyelitis, J. Immunol., 176, 4399, 10.4049/jimmunol.176.7.4399 · DOI
  49. Lasch, 2015, Anti-CD3/anti-CXCL10 antibody combination therapy induces a persistent remission of type 1 diabetes in two mouse models, Diabetes, 64, 4198, 10.2337/db15-0479 · DOI
  50. Reininger, 1996, T helper cell subsets in the pathogenesis of systemic lupus erythematosus, Ann. Med. Intern. (Paris), 147, 467
  51. Van Raemdonck, 2015, CXCR3 ligands in disease and therapy, Cytokine Growth Factor Rev., 26, 311, 10.1016/j.cytogfr.2014.11.009 · DOI
  52. Enghard, 2009, CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients, Arthritis Rheum., 60, 199, 10.1002/art.24136 · DOI
  53. Okamoto, 2012, Kidney-infiltrating CD4+ T-cell clones promote nephritis in lupus-prone mice, Kidney Int., 82, 969, 10.1038/ki.2012.242 · DOI
  54. Cortes, 2008, Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature, Lupus, 17, 977, 10.1177/0961203308091539 · DOI
  55. Dong, 2008, Dendritic cells facilitate accumulation of IL-17 T cells in the kidney following acute renal obstruction, Kidney Int., 74, 1294, 10.1038/ki.2008.394 · DOI
  56. Paust, 2009, The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis, J. Am. Soc. Nephrol., 20, 969, 10.1681/ASN.2008050556 · DOI
  57. Tulone, 2011, Transferred antigen-specific T(H)17 but not T(H)1 cells induce crescentic glomerulonephritis in mice, Am. J. Pathol., 179, 2683, 10.1016/j.ajpath.2011.08.017 · DOI
  58. Azadegan-Dehkordi, 2015, The role of Th1 and Th17 cells in glomerulonephritis, J. Nephropathol., 4, 32
  59. Groom, 2011, CXCR3 ligands: redundant, collaborative and antagonistic functions, Immunol. Cell Biol., 89, 207, 10.1038/icb.2010.158 · DOI
  60. Tamassia, 2007, Molecular mechanisms underlying the synergistic induction of CXCL10 by LPS and IFN-gamma in human neutrophils, Eur. J. Immunol., 37, 2627, 10.1002/eji.200737340 · DOI
  61. Powell, 2004, Identification of the molecular mechanism by which TLR ligation and IFN-gamma synergize to induce MIG, Clin. Dev. Immunol., 11, 77, 10.1080/10446670410001670535 · DOI
  62. Horton, 1998, Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages, J. Biol. Chem., 273, 35088, 10.1074/jbc.273.52.35088 · DOI
  63. Kopydlowski, 1999, Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo, J. Immunol., 163, 1537, 10.4049/jimmunol.163.3.1537 · DOI
  64. Sheikh, 2014, An essential role for IFN-beta in the induction of IFN-stimulated gene expression by LPS in macrophages, J. Leukoc. Biol., 96, 591, 10.1189/jlb.2A0414-191R · DOI
  65. Majumder, 1998, p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha, J. Immunol., 161, 4736, 10.4049/jimmunol.161.9.4736 · DOI
  66. Coma, 2006, Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10, Clin. Exp. Immunol., 145, 535, 10.1111/j.1365-2249.2006.03145.x · DOI
  67. Lee-Sayer, 2015, The where, when, how, and why of hyaluronan binding by immune cells, Front. Immunol., 6, 150, 10.3389/fimmu.2015.00150 · DOI
  68. Esplugues, 2011, Control of TH17 cells occurs in the small intestine, Nature, 475, 514, 10.1038/nature10228 · DOI
  69. Li, 2013, Recruitment of CCR6-expressing Th17 cells by CCL20 secreted from plasmin-stimulated macrophages, Acta Biochim. Biophys. Sin., 45, 593, 10.1093/abbs/gmt049 · DOI
  70. Bianco, 1990, Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues, J. Histochem. Cytochem., 38, 1549, 10.1177/38.11.2212616 · DOI
  71. Kang, 2011, Structural biology of the toll-like receptor family, Annu. Rev. Biochem., 80, 917, 10.1146/annurev-biochem-052909-141507 · DOI
  72. Ng, 2011, Leucine-rich repeat (LRR) proteins: integrators of pattern recognition and signaling in immunity, Autophagy, 7, 1082, 10.4161/auto.7.9.16464 · DOI
  73. Matsushima, 2000, Super-motifs and evolution of tandem leucine-rich repeats within the small proteoglycans–biglycan, decorin, lumican, fibromodulin, PRELP, keratocan, osteoadherin, epiphycan, and osteoglycin, Proteins, 38, 210, 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1 · DOI
  74. Andrews, 2016, Small molecule CXCR3 antagonists, J. Med. Chem., 59, 2894, 10.1021/acs.jmedchem.5b01337 · DOI
  75. Xu, 1998, Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice, Nat. Genet., 20, 78, 10.1038/1746 · DOI
  76. Adachi, 1998, Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function, Immunity, 9, 143, 10.1016/S1074-7613(00)80596-8 · DOI
  77. Hoebe, 2003, Identification of Lps2 as a key transducer of MyD88-independent TIR signalling, Nature, 424, 743, 10.1038/nature01889 · DOI
  78. Dufour, 2002, IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking, J. Immunol., 168, 3195, 10.4049/jimmunol.168.7.3195 · DOI · Paper page

Cited by

Sorted by citations

See all 60

Metadata

Authors
Nastase, M. V., Zeng-Brouwers, J., Beckmann, J., Tredup, C., Christen, U., Radeke, H. H., Wygrecka, M., & Schaefer, L.
ORCID
Venue
Matrix Biology
Publisher
Elsevier BV
Published
2018-08
Volume
68-69
Pages
293-317
ISSN
0945-053X
DOI
10.1016/j.matbio.2017.12.002
Cited by
60
References
4
Language
en
Update notices
erratum (2026-06-01)
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • German Research Council (SFB 815, SFB 1039, SFB 1177, SCHA 1082/6-1, WY119/1-3)
  • German Center for Lung Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review